Amplia Therapeutics Ltd (ASX:ATX) CEO and managing director Dr John Lambert speaks with Proactive’s Andrew Scott about its clinical trial of focal adhesion kinase (FAK) inhibitor AMP945 for the treatment of patients with advanced pancreatic cancer. AMP945 use is intended to increase the efficacy of gemcitabine/nab-paclitaxel chemotherapy for people with advanced pancreatic cancer undergoing first-line treatment.
Amplia Therapeutics achieves critical clinical milestone for lead cancer therapy
